ABVC BioPharma Secures $450K from OncoX, Boosting Oncology Alliance

ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company, has received $450,000 in licensing payments from its partner OncoX BioPharma during the third quarter of 2025, including $350,000 in August alone. This financial injection underscores the robust strategic alliance between the two companies and highlights the growing commercial potential of ABVC's oncology pipeline. The partnership, which covers four major oncology indications—Triple Negative Breast Cancer (TNBC), Non-Small Cell Lung Cancer (NSCLC), Myelodysplastic Syndromes (MDS), and Pancreatic Cancer—has already secured ABVC $650,000 in cash to date, with $1.85 million remaining receivable and 5 million OncoX shares in hand. The total deal value, including equity and future royalties, is estimated at over $100 million, positioning ABVC strongly in the rapidly expanding global cancer therapeutics market, projected to reach $469.38 billion by 2034.

Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized the execution strength of the collaboration, noting that at the group level, including subsidiary BioLite, ABVC is entitled to $3.75 million in total cash consideration and 7.5 million OncoX shares. This not only provides immediate liquidity but also long-term equity value. OncoX's CEO echoed this sentiment, highlighting the partnership's alignment with their vision of combining innovation with strategic collaborations to capitalize on the booming oncology market. The licensing agreement, coupled with OncoX's recent acquisition of the Lycogen® platform for $4.06 million, demonstrates a committed effort to expand their oncology portfolio and prepare for global opportunities. Both companies are leveraging botanical-derived drug candidates, all of which have received FDA IND approvals, signaling strong development progress and regulatory backing.

The collaboration is set against a backdrop of a cancer therapeutics market valued at approximately $194.67 billion in 2024, with a compound annual growth rate (CAGR) of 9.2%. This substantial growth potential, as reported by Precedence Research, underscores the significant commercial opportunity for ABVC and OncoX. The partnership not only strengthens ABVC's strategic positioning in oncology but also creates a framework with consolidated value exceeding $41 million, excluding future royalties. For more details, visit the original release on www.newmediawire.com. This news highlights ABVC's leadership in advancing innovative, botanical-derived therapies toward global commercialization, backed by a network of renowned research institutions like Stanford University and UCSF.